Daewoong Pharmaceutical Co (XKRX:069620) Ending Cash Position : ₩102,950 Mil (As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Daewoong Pharmaceutical Co Ending Cash Position?

Daewoong Pharmaceutical Co's Ending Cash Position for the quarter that ended in Dec. 2024 was ₩102,950 Mil.

Daewoong Pharmaceutical Co's quarterly Ending Cash Position increased from Jun. 2024 (₩87,679 Mil) to Sep. 2024 (₩94,570 Mil) and increased from Sep. 2024 (₩94,570 Mil) to Dec. 2024 (₩102,950 Mil).

Daewoong Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2022 (₩102,951 Mil) to Dec. 2023 (₩111,506 Mil) but then declined from Dec. 2023 (₩111,506 Mil) to Dec. 2024 (₩102,950 Mil).

Daewoong Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Daewoong Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewoong Pharmaceutical Co Ending Cash Position Chart

Daewoong Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

72,299.25

75,907.31

102,951.26

111,506.19

102,950.42

Daewoong Pharmaceutical Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															111,506.19	105,768.13	87,678.86	94,570.37	102,950.42

Daewoong Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Daewoong Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	111506.188	+	-8555.768
	=	102,950

Daewoong Pharmaceutical Co's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	94570.369	+	8380.051
	=	102,950

Daewoong Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Daewoong Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Daewoong Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewoong Pharmaceutical Co Ltd (XKRX:069620) » Definitions » Ending Cash Position

Traded in Other Exchanges

N/A

Address

12, Bongeunsa-ro 114-gil, Daewoong Pharmaceutical Building, Gangnam-gu, Seoul, KOR

Website

https://www.daewoong.co.kr

Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Daewoong Pharmaceutical Co Headlines

No Headlines